InterVene, based in Redwood City, CA, is a clinical-stage medical device company focused on interventional technology for treatment and prophylaxis of causes of chronic venous insufficiency (CVI), with emphasis on severe deep venous disease. Its core product, the Recana catheter system, is designed to recanalize and restore patency in chronically obstructed deep veins and venous stents, particularly when recanalization capabilities are limited or when long-term chronic stent maintenance is necessary. Recana utilizes standard Fluoroscopy/IVUS-guided interventional techniques and can be incorporated by vascular specialists already performing deep vein thrombosis (DVT) treatment and deep venous stenting. Led by CEO Jeff Elkins and staffed by interventional cardiovascular professionals, the company was formed with assistance from the Stanford Biodesign Fellowship program and was a former Company-In-Residence at the Fogarty Institute for Innovation. InterVene plans to use the funding to finalize Recana development, initiate clinical cases, pursue regulatory submission and U.S. market clearance, and prepare for initial commercialization. Proceeds will also support post-market clinical research. InterVene's BlueLeaf Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) designed to form new venous valves from a patient’s own vein wall tissue without an implant. The system allows physicians to fashion autogenous valves intended to reduce retrograde blood flow and alleviate symptoms of chronic venous insufficiency (CVI). The BlueLeaf technique is predicated on the Maleti Neovalve open-surgical procedure but mechanizes and miniaturizes it to avoid open surgery, enable multiple valves in a single procedure, and improve repeatability. Approximately 6.5 million Americans suffer from DVR and moderate to severe CVI, indicating a substantial addressable patient population. InterVene plans to expand its clinical research program abroad and to initiate U.S. trials via an Investigational Device Exemption study while optimizing the system and procedure. The company has recently expanded its management team, adding COO Jeff Elkins and VP clinical affairs Tracy Roberts to support clinical and commercial development. InterVene has developed a minimally invasive, catheter-based therapy that creates venous leaflets from the intima of a patient’s own vein wall to function as one-way deep vein valves. The device is non-implantable and is predicated on the open-surgical Maleti Neovalve procedure, aiming to restore normal venous pressure and prevent blood pooling that leads to venous ulcers. The company plans a two-stage clinical trial to demonstrate clinical functionality and acute safety. The initial closing of $5.9 million in Series A funding will support those trials. InterVene originated from the Stanford Biodesign Fellowship and advanced through work with The Fogarty Institute for Innovation. The company is based in Mountain View, Calif., and is moving to a new facility in Silicon Valley.

Total raised

$34M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2024